{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T22:35:20Z","timestamp":1784241320881,"version":"3.55.0"},"reference-count":44,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,2,20]],"date-time":"2025-02-20T00:00:00Z","timestamp":1740009600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1016\/j.ejca.2025.115306","type":"journal-article","created":{"date-parts":[[2025,2,18]],"date-time":"2025-02-18T00:14:52Z","timestamp":1739837692000},"page":"115306","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"special_numbering":"C","title":["Tumor Treating Fields therapy in platinum-resistant ovarian cancer: Results of the ENGOT-ov50\/GOG-3029\/INNOVATE-3 pivotal phase 3 randomized study"],"prefix":"10.1016","volume":"219","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7589-8981","authenticated-orcid":false,"given":"Ignace","family":"Vergote","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6204-0962","authenticated-orcid":false,"given":"Larry J.","family":"Copeland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2564-721X","authenticated-orcid":false,"given":"Toon","family":"Van Gorp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1371-442X","authenticated-orcid":false,"given":"Annouschka","family":"Laenen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Scambia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Premal H.","family":"Thaker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6387-9356","authenticated-orcid":false,"given":"David","family":"Cibula","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicoletta","family":"Colombo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jayanthi","family":"Lea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8376-9576","authenticated-orcid":false,"given":"Antonio","family":"Gonzalez-Martin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacob","family":"Korach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jalid","family":"Sehouli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6985-0159","authenticated-orcid":false,"given":"Bradley J.","family":"Monk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Viola","family":"Heinzelmann-Schwarz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Regina","family":"Berger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Buscema","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susie","family":"Lau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Radoslaw","family":"M\u0105dry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8897-9430","authenticated-orcid":false,"given":"Hannelore","family":"Denys","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica Thomes","family":"Pepin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vanda","family":"Salutari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Bagam\u00e9ri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Ardizzoia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4704-4647","authenticated-orcid":false,"given":"St\u00e9phanie","family":"Henry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabrina Chiara","family":"Cecere","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7606-5164","authenticated-orcid":false,"given":"Martin","family":"Hruda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David A.","family":"Iglesias","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1683-550X","authenticated-orcid":false,"given":"Luis","family":"Manso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9502-8441","authenticated-orcid":false,"given":"Ayelet","family":"Shai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David M.","family":"O\u2019Malley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejca.2025.115306_bib1","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.21037\/gs-20-325","article-title":"Secondary and tertiary ovarian cancer recurrence: what is the best management?","volume":"9","author":"Garzon","year":"2020","journal-title":"Gland Surg"},{"key":"10.1016\/j.ejca.2025.115306_bib2","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1200\/GO.21.00085","article-title":"Assessment of adult women with ovarian masses and treatment of epithelial ovarian cancer: ASCO resource-stratified guideline","volume":"7","author":"Vanderpuye","year":"2021","journal-title":"JCO Glob Oncol"},{"key":"10.1016\/j.ejca.2025.115306_bib3","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1093\/annonc\/mdz062","article-title":"ESMO-ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent diseasedagger","volume":"30","author":"Colombo","year":"2019","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2025.115306_bib4","unstructured":"National Comprehensive Care Network. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae): ovarian cancer including fallopian tube cancer and primary peritoneal cancer; 2024."},{"key":"10.1016\/j.ejca.2025.115306_bib5","doi-asserted-by":"crossref","first-page":"2162","DOI":"10.1056\/NEJMoa2309169","article-title":"Mirvetuximab soravtansine in FR\u03b1-positive, platinum-resistant ovarian cancer","volume":"389","author":"Moore","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2025.115306_bib6","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/j.annonc.2021.02.017","article-title":"Phase III, randomized trial of mirvetuximab soravtansine versus chemotherapy in patients with platinum-resistant ovarian cancer: primary analysis of FORWARD I","volume":"32","author":"Moore","year":"2021","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2025.115306_bib7","doi-asserted-by":"crossref","first-page":"18046","DOI":"10.1038\/srep18046","article-title":"Mitotic spindle disruption by alternating electric fields leads to improper chromosome segregation and mitotic catastrophe in cancer cells","volume":"5","author":"Giladi","year":"2015","journal-title":"Sci Rep"},{"key":"10.1016\/j.ejca.2025.115306_bib8","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1038\/s41419-018-1085-9","article-title":"AMPK-dependent autophagy upregulation serves as a survival mechanism in response to tumor treating fields (TTFields)","volume":"9","author":"Shteingauz","year":"2018","journal-title":"Cell Death Dis"},{"key":"10.1016\/j.ejca.2025.115306_bib9","doi-asserted-by":"crossref","first-page":"3016","DOI":"10.3390\/cancers12103016","article-title":"Tumor Treating Fields (TTFields) hinder cancer cell motility through regulation of microtubule and acting dynamics","volume":"12","author":"Voloshin","year":"2020","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.ejca.2025.115306_bib10","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.trsl.2019.10.003","article-title":"Tumor treating fields cause replication stress and interfere with DNA replication fork maintenance: implications for cancer therapy","volume":"217","author":"Karanam","year":"2020","journal-title":"Transl Res"},{"key":"10.1016\/j.ejca.2025.115306_bib11","doi-asserted-by":"crossref","first-page":"3288","DOI":"10.1158\/0008-5472.CAN-04-0083","article-title":"Disruption of cancer cell replication by alternating electric fields","volume":"64","author":"Kirson","year":"2004","journal-title":"Cancer Res"},{"key":"10.1016\/j.ejca.2025.115306_bib12","doi-asserted-by":"crossref","first-page":"10152","DOI":"10.1073\/pnas.0702916104","article-title":"Alternating electric fields arrest cell proliferation in animal tumor models and human brain tumors","volume":"104","author":"Kirson","year":"2007","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.ejca.2025.115306_bib13","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1038\/s41420-018-0130-x","article-title":"Tumor treating fields increases membrane permeability in glioblastoma cells","volume":"4","author":"Chang","year":"2018","journal-title":"Cell Death Discov"},{"key":"10.1016\/j.ejca.2025.115306_bib14","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1007\/s11060-024-04740-0","article-title":"Effects of tumor treating fields (TTFields) on human mesenchymal stromal cells","volume":"169","author":"Strack","year":"2024","journal-title":"J Neurooncol"},{"key":"10.1016\/j.ejca.2025.115306_bib15","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0179214","article-title":"Impact of tumor position, conductivity distribution and tissue homogeneity on the distribution of tumor treating fields in a human brain: a computer modeling study","volume":"12","author":"Korshoej","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.ejca.2025.115306_bib16","doi-asserted-by":"crossref","first-page":"2850","DOI":"10.1002\/ijc.30406","article-title":"Alternating electric fields (TTFields) in combination with paclitaxel are therapeutically effective against ovarian cancer cells in vitro and in vivo","volume":"139","author":"Voloshin","year":"2016","journal-title":"Int J Cancer"},{"key":"10.1016\/j.ejca.2025.115306_bib17","unstructured":"Novocure Inc. FDA approves the NovoTTF-100LTM system in combination with chemotherapy for the treatment of malignant pleural mesothelioma. Available at: \u3008https:\/\/www.novocure.com\/fda-approves-the-novottf-100ltm-system-in-combination-with-chemotherapy-for-the-treatment-of-malignant-pleural-mesothelioma\/\u3009. Accessed January 25, 2024."},{"key":"10.1016\/j.ejca.2025.115306_bib18","unstructured":"Novocure Inc. FDA Approves Novocure\u2019s Optune Lua\u00ae for the Treatment of Metastatic Non-Small Cell Lung Cancer. Available at: \u3008https:\/\/www.novocure.com\/fda-approves-novocures-optune-lua-for-the-treatment-of-metastatic-non-small-cell-lung-cancer\/\u3009. Accessed October 28, 2024."},{"key":"10.1016\/j.ejca.2025.115306_bib19","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/j.ygyno.2018.07.018","article-title":"Tumor treating fields in combination with paclitaxel in recurrent ovarian carcinoma: results of the INNOVATE pilot study","volume":"150","author":"Vergote","year":"2018","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ejca.2025.115306_bib20","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.ygyno.2019.04.677","article-title":"Joint ENGOT and GOG Foundation requirements for trials with industry partners","volume":"154","author":"Vergote","year":"2019","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ejca.2025.115306_bib21","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1016\/S1470-2045(21)00216-3","article-title":"Avelumab alone or in combination with chemotherapy versus chemotherapy alone in platinum-resistant or platinum-refractory ovarian cancer (JAVELIN Ovarian 200): an open-label, three-arm, randomised, phase 3 study","volume":"22","author":"Pujade-Lauraine","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2025.115306_bib22","unstructured":"Hamanishi J.A.-O., Takeshima N., Katsumata N., et al. Nivolumab Versus Gemcitabine or Pegylated Liposomal Doxorubicin for Patients With Platinum-Resistant Ovarian Cancer: Open-Label, Randomized Trial in Japan (NINJA)."},{"key":"10.1016\/j.ejca.2025.115306_bib23","doi-asserted-by":"crossref","first-page":"1258228","DOI":"10.3389\/fonc.2023.1258228","article-title":"Overcoming the challenges of drug development in platinum-resistant ovarian cancer","volume":"13","author":"Eskander","year":"2023","journal-title":"Front Oncol"},{"key":"10.1016\/j.ejca.2025.115306_bib24","unstructured":"Richardson D.L., Eskander R.N., O'Malley D.M. Advances in ovarian cancer care and unmet treatment needs for patients with platinum resistance: a narrative review."},{"key":"10.1016\/j.ejca.2025.115306_bib25","series-title":"Efficacy and safety of alpelisib plus olaparib versus chemotherapy among patients with platinum-resistant or refractory high-grade serous ovarian cancer without BRCA mutation: Primary analysis of the EPIK-O trial","first-page":"2024","author":"Konstantinopoulos","year":"2024"},{"key":"10.1016\/j.ejca.2025.115306_bib26","unstructured":"Aravive Announces Top-Line Results from Phase 3 AXLerate-OC Study of Batiraxcept in Platinum-Resistant Ovarian Cancer. BioSpace. Available at: \u3008https:\/\/www.biospace.com\/aravive-announces-top-line-results-from-phase-3-axlerate-oc-study-of-batiraxcept-in-platinum-resistant-ovarian-cancer\u3009. Accessed July 24, 2024."},{"key":"10.1016\/j.ejca.2025.115306_bib27","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2024.42.17_suppl.LBA5515","article-title":"AXLerate-OC\/GOG-3059\/ENGOT OV-66: Results of a phase 3, randomized, double-blind, placebo\/paclitaxel-controlled study of batiraxcept (AVB-S6-500) in combination with paclitaxel in patients with platinum-resistant recurrent ovarian cancer","volume":"42","author":"Fuh","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2025.115306_bib28","first-page":"15","article-title":"Prognostic factors influencing survival in ovarian cancer patients: a 10-year retrospective study","author":"Andreou","year":"2023","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.ejca.2025.115306_bib29","doi-asserted-by":"crossref","first-page":"2605","DOI":"10.1093\/annonc\/mds203","article-title":"The impact of second to sixth line therapy on survival of relapsed ovarian cancer after primary taxane\/platinum-based therapy","volume":"23","author":"Hanker","year":"2012","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2025.115306_bib30","unstructured":"Novocure. Data on File. In; 2024."},{"key":"10.1016\/j.ejca.2025.115306_bib31","doi-asserted-by":"crossref","unstructured":"Vergote I., Copeland L., Van Gorp T., et al. Tumor Treating Fields (TTFields) therapy in platinum-resistant ovarian cancer: Results from the ENGOT-ov50\/GOG-3029\/ INNOVATE-3 phase 3 study. In: European Society of Gynaecological Oncology (ESGO); 2024 Mar 7-10; Barcelona, Spain; 2024.","DOI":"10.1136\/ijgc-2024-ESGO.1121"},{"key":"10.1016\/j.ejca.2025.115306_bib32","doi-asserted-by":"crossref","DOI":"10.1016\/j.tranon.2021.101076","article-title":"Type of chemotherapy has substantial effects on the immune system in ovarian cancer","volume":"14","author":"Vankerckhoven","year":"2021","journal-title":"Transl Oncol"},{"key":"10.1016\/j.ejca.2025.115306_bib33","unstructured":"U.S. Food and Drug Administration. ELAHERE (mirvetuximab soravtansine-gynx) full prescribing information. Available at: \u3008https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2022\/761310s000lbl.pdf\u3009. Accessed December 20, 2022."},{"key":"10.1016\/j.ejca.2025.115306_bib34","doi-asserted-by":"crossref","first-page":"2436","DOI":"10.1200\/JCO.22.01900","article-title":"Efficacy and Safety of Mirvetuximab Soravtansine in Patients With Platinum-Resistant Ovarian Cancer With High Folate Receptor Alpha Expression: Results From the SORAYA Study","volume":"41","author":"Matulonis","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2025.115306_bib35","series-title":"paclitaxel","article-title":"TAXOL","author":"Bristol-Myers Squibb Company","year":"2011"},{"key":"10.1016\/j.ejca.2025.115306_bib36","doi-asserted-by":"crossref","first-page":"2654","DOI":"10.1200\/JCO.1994.12.12.2654","article-title":"European-Canadian randomized trial of paclitaxel in relapsed ovarian cancer: high-dose versus low-dose and long versus short infusion","volume":"12","author":"Eisenhauer","year":"1994","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.ejca.2025.115306_bib37","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1053\/j.seminoncol.2014.03.011","article-title":"Characterization and management of dermatologic adverse events with the NovoTTF-100A System, a novel anti-mitotic electric field device for the treatment of recurrent glioblastoma","volume":"41","author":"Lacouture","year":"2014","journal-title":"Semin Oncol"},{"key":"10.1016\/j.ejca.2025.115306_bib38","doi-asserted-by":"crossref","first-page":"2306","DOI":"10.1001\/jama.2017.18718","article-title":"Effect of tumor-treating fields plus maintenance temozolomide vs maintenance temozolomide alone on survival in patients with glioblastoma: a randomized clinical trial","volume":"318","author":"Stupp","year":"2017","journal-title":"JAMA"},{"key":"10.1016\/j.ejca.2025.115306_bib39","doi-asserted-by":"crossref","first-page":"1702","DOI":"10.1016\/S1470-2045(19)30532-7","article-title":"Tumour treating fields in combination with pemetrexed and cisplatin or carboplatin as first-line treatment for unresectable malignant pleural mesothelioma (STELLAR): a multicentre, single-arm phase 2 trial","volume":"20","author":"Ceresoli","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2025.115306_bib40","first-page":"14","article-title":"Tumor Treating Fields concomitant with sorafenib in advanced hepatocellular cancer: results of the HEPANOVA phase II study","author":"Gkika","year":"2022","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.ejca.2025.115306_bib41","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.pan.2018.10.004","article-title":"Tumor Treating Fields in combination with gemcitabine or gemcitabine plus nab-paclitaxel in pancreatic cancer: results of the PANOVA phase 2 study","volume":"19","author":"Rivera","year":"2019","journal-title":"Pancreatology"},{"key":"10.1016\/j.ejca.2025.115306_bib42","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1016\/S1470-2045(23)00344-3","article-title":"Tumor Treating Fields therapy with standard systemic therapy versus standard systemic therapy alone in metastatic non-small-cell lung cancer following progression on or after platinum-based therapy (LUNAR): a randomised, open-label, pivotal phase 3 study","volume":"24","author":"Leal","year":"2023","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2025.115306_bib43","doi-asserted-by":"crossref","first-page":"2049","DOI":"10.1200\/JCO.2023.41.16_suppl.2049","article-title":"Post-marketing surveillance safety analysis of patients with CNS malignancies treated with tumor treating fields (TTFields) therapy between 2011\u20132022","volume":"41","author":"Mrugala","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2025.115306_bib44","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.975473","article-title":"Expert guidance on prophylaxis and treatment of dermatologic adverse events with Tumor Treating Fields (TTFields) therapy in the thoracic region","volume":"12","author":"Anadkat","year":"2023","journal-title":"Front Oncol"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804925000875?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804925000875?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,3,10]],"date-time":"2025-03-10T09:06:43Z","timestamp":1741597603000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804925000875"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":44,"alternative-id":["S0959804925000875"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2025.115306","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2025,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Tumor Treating Fields therapy in platinum-resistant ovarian cancer: Results of the ENGOT-ov50\/GOG-3029\/INNOVATE-3 pivotal phase 3 randomized study","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2025.115306","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"115306"}}